Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 7/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27961681 | 0.85 | AR (0.42) | POLBSLC22A12ARPGRALDH1A1 | |
| SCHEMBL29182356 | 0.84 | GAA (0.43) | GAAPOLBTSHRARPGR | |
| SCHEMBL29209813 | 0.84 | MPL (0.42) | GAAPOLBSLC22A12FFAR1AR | |
| SCHEMBL28000167 | 0.84 | GAA (0.43) | GAAPOLBSLC22A12TSHRAR | |
| SCHEMBL17205098 | 0.81 | GAA (0.41) | GAAPOLBTSHRARPGR | |
| SCHEMBL22979039 | 0.81 | SLC22A12 (0.39) | GAAPOLBSLC22A12FFAR1AR | |
| SCHEMBL17202292 | 0.80 | GAA (0.40) | GAAPOLBTSHRARPGR | |
| SCHEMBL11568266 | 0.79 | GAA (0.46) | GAAPOLBTSHRARHTR1A | |
| SCHEMBL4292100 | 0.79 | FFAR1 (0.42) | GAAPOLBSLC22A12FFAR1ALDH1A1 | |
| SCHEMBL96814 | 0.79 | FFAR1 (0.46) | GAAPOLBSLC22A12FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630117-A1 | COMPOUNDS FOR THE TREATMENT OF CENTRA NERVOUS SYSTEM DISORDERS | Autifony Therapeutics Limited (GB) | 2025-10-15 | — | — | EP | claimed |
| WO-2024121552-A1 | COMPOUNDS FOR THE TREATMENT OF CENTRA NERVOUS SYSTEM DISORDERS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2024-06-13 | — | — | WO | claimed |
| CN-109952289-B | TRPV4 antagonists | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-115403570-A | Mu-opioid receptor agonist, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2022-11-29 | — | — | CN | claimed |
| EP-4038054-A1 | PYRIMIDINEDIONE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2022-08-10 | — | — | EP | claimed |
| WO-2021063821-A1 | PYRIMIDINEDIONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-08 | — | — | WO | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| EP-4630117-A1 | COMPOUNDS FOR THE TREATMENT OF CENTRA NERVOUS SYSTEM DISORDERS | Autifony Therapeutics Limited (GB) | 2025-10-15 | — | — | EP | disclosed |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-03 | — | — | US | disclosed |
| CN-115403570-B | Mu-opioid receptor agonist, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240327406-A1 | POTASSIUM CHANNEL MODULATORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| US-6162942-A | Method for producing aromatic nitriles | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-19 | — | — | US | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| EP-1019410-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2000-07-19 | — | — | EP | disclosed |
| WO-1997019084-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| EP-0365914-A2 | Fluorine-containing acetophenones optionally halogenated in the CH3-group, and their preparation from fluorinated benzonitriles | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
| EP-0365913-A2 | Substituted 2-aminothiazoles | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
| EP-0354689-A1 | Diphenylethane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327406-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNN2, KCNN1 | GAA 3559/4885POLB 4686/4885SLC22A12 966/4885 |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | GAA 3801/4885POLB 3410/4885SLC22A12 4758/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | GAA 653/4885POLB 592/4885SLC22A12 1115/4885 |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | GAA 3801/4885POLB 3410/4885SLC22A12 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.